CMV specific T cells + AdV specific T cells

This is a combination cell therapy product consisting of cytomegalovirus (CMV)-specific and adenovirus (AdV)-specific T lymphocytes. These are ex vivo expanded or directly isolated populations of donor-derived or third-party virus-specific CD4+ and CD8+ T-cells that recognize antigens from CMV and/or AdV. The therapy is designed to restore antiviral immunity in immunocompromised patients—most commonly after allogeneic hematopoietic stem cell transplantation (allo-HCT)—who are at high risk for severe or refractory viral infections due to impaired immune reconstitution. The mechanism involves adoptive transfer of these virus-targeted effector/memory T-cells, which can recognize infected host cells via HLA-restricted viral peptide presentation, leading to targeted elimination of infected cells through cytotoxicity and cytokine production. This approach has shown efficacy in reducing viral load for both CMV and AdV infections where conventional antivirals are limited by toxicity or resistance[1][3][4][6][10]. Manufacturing may involve stimulation with viral peptides/proteins followed by expansion/selection; products may be derived from the original stem cell donor or a partially HLA-matched third-party donor.

Other names

CMV-specific T cells + AdV-specific T cellscytomegalovirus-specific T cells + adenovirus-specific T cellsvirus-specific T-cell therapy (CMV and AdV)VSTs (CMV and AdV)